1) 市川陽一:副腎皮質ステロイド. 診断と治療, 88:413-422, 診断と治療社, 2000
2) 三森経世:副腎皮質ステロイド. 「治療薬ガイド2003-2004」(Medical Practice編集委員会/編), pp774-782, 文光堂, 2003
3) Weening JJ, et al:The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int, 65:521-530, 2004
4) Austin HA 3rd, et al:Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med, 75:382-391, 1983
5) Tokunaga M, et al:Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis, 66:470-475, 2007
6) Chatham WW & Kimberly RP:Treatment of lupus with corticosteroids. Lupus, 10:140-147, 2001
7) Boumpas DT, et al:Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet, 340:741-745, 1992
8) 高崎芳成:難治性ループス腎炎. 「全身性自己免疫疾患における難治性病態の診療ガイドライン」(三森経世/編), pp50-54, 厚生労働省免疫アレルギー疾患予防・治療研究事業全身性自己免疫疾患における難治性病態の診断と治療法に関する研究班, 2005
9) Olsen NJ & Wortmann RL.:Inflammatory and metabolic diseases of muscle. Primer on the Rheumatic Diseases 11th edition (Klippel JH, et al, eds), pp276-282, Arthritis Foundation, 1997
10) Oddis CV:Idiopathic inflammatory myopathy:management and prognosis. Rheum Dis Clin North Am, 28:979-1001, 2002
11) Vencovsky J, et al:Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol, 29:95-102, 2000
12) Dalakas MC, et al:A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med, 329:1993-2000, 1993
13) 平形道人:ステロイド抵抗性筋炎. 「全身性自己免疫疾患における難治性病態の診療ガイドライン」(三森経世/編), pp10-16, 厚生労働省免疫アレルギー疾患予防・治療研究事業全身性自己免疫疾患における難治性病態の診断と治療法に関する研究班, 2005
14) 山田秀裕:PM/DMの急性間質性肺炎. 「全身性自己免疫疾患における難治性病態の診療ガイドライン」(三森経世/編), pp23-28, 厚生労働省免疫アレルギー疾患予防・治療研究事業全身性自己免疫疾患における難治性病態の診断と治療法に関する研究班, 2005
15) Mimori T, et al:Interstitial lung disease in myositis:clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep, 14:264-274, 2012
16) 中嶋蘭, 他:抗MDA5 (melanoma differentiation-associated gene 5) 抗体と皮膚筋炎・急速進行性間質性肺炎. 日本臨床免疫学会会誌, 36:71-76, 2013
17) Jennette JC, et al:2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum, 65:1-11, 2013
18) 古川福実, 他:血管炎・血管障害診療ガイドライン2016年改訂版. 日皮会誌, 127:299-415, 2017
19) 「関節リウマチ診療ガイドライン 2014」(日本リウマチ学会/編), メディカルレビュー社, 2014
20) Singh JA, et al:2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol, 68:1-26, 2016
21) Smolen JS, et al:EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs:2016 update. Ann Rheum Dis, 76:960-977, 2017
22) Kirwan JR:The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med, 333:142-146, 1995
23) Umehara H, et al:Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol, 22:21-30, 2012
24) Umehara H, et al:A novel clinical entity, IgG4-related disease (IgG4RD):general concept and details. Mod Rheumatol, 22:1-14, 2012
25) de Jesus AA & Goldbach-Mansky R:Monogenic autoinflammatory diseases:concept and clinical manifestations. Clin Immunol, 147:155-174, 2013
26) de Jesus AA, et al:Molecular mechanisms in genetically defined autoinflammatory diseases:disorders of amplified danger signaling. Annu Rev Immunol, 33:823-874, 2015
27) 自己炎症性疾患サイト:http://aid.kazusa.or.jp/2013/
28) Ter Haar N, et al:Treatment of autoinflammatory diseases:results from the Eurofever Registry and a literature review. Ann Rheum Dis, 72:678-685, 2013
29) Kallinich T:Regulating against the dysregulation:new treatment options in autoinflammation. Semin Immunopathol, 37:429-437, 2015
30) Barnes PJ:Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol, 120:76-85, 2010